Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124253 | 0.89 | NOTUM (0.65) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL15743832 | 0.87 | NOTUM (0.61) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL27536609 | 0.87 | NOTUM (0.61) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL8803741 | 0.85 | NOTUM (0.60) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL14665068 | 0.84 | NOTUM (0.58) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL27536610 | 0.84 | NOTUM (0.58) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL14663963 | 0.84 | NOTUM (0.58) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL16508643 | 0.83 | NOTUM (0.57) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL7825717 | 0.83 | NOTUM (0.57) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 | |
| SCHEMBL14664037 | 0.82 | NOTUM (0.56) | CYP11B1CYP11B2NOTUMRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-0431943-B1 | Spiro(pyran)piperidine derivatives | MERCK & CO INC (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | CYP11B1 4289/4885CYP11B2 4519/4885NOTUM 2877/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | CYP11B1 4289/4885CYP11B2 4519/4885NOTUM 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.